Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer

被引：0
|
作者：
Javle, M. [1 ]
Fogelman, D. [1 ]
Kaseb, A. [1 ]
Varadhachary, G. [1 ]
Wolff, R. [1 ]
Abbruzzese, J. [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72262-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：104 / 104
页数：1
相关论文
共 50 条
  • [21] A phase II study of docetaxel (D) followed by flavopiridol (F) in advanced, gemcitabine-refractory pancreatic cancer (PC)
    Carvajal, R. D.
    Shah, M. A.
    Tse, A.
    Lefkowitz, R.
    Kelsen, D. P.
    Schwartz, G. K.
    O'Reilly, E. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Morizane, Chigusa
    Okusaka, Takuji
    Furuse, Junji
    Ishii, Hiroshi
    Ueno, Hideki
    Ikeda, Masafumi
    Nakachi, Kohei
    Najima, Mina
    Ogura, Takashi
    Suzuki, Eiichiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (02) : 313 - 319
  • [23] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Chigusa Morizane
    Takuji Okusaka
    Junji Furuse
    Hiroshi Ishii
    Hideki Ueno
    Masafumi Ikeda
    Kohei Nakachi
    Mina Najima
    Takashi Ogura
    Eiichiro Suzuki
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 313 - 319
  • [24] Phase II trial of the oral mTOR inhibitor RAD001 (everolimus) in relapsed and/or refractory Waldenstrom Macroglobulinemia: Preliminary results
    Ghobrial, Irene M.
    Leduc, Renee
    Nelson, Marybeth
    Leleu, Xavier
    Jacobsen, Eric
    LaCasce, Ann
    DeAngelo, Daniel
    Fisher, David
    Brown, Jennifer R.
    Schlossman, Robert
    Warren, Diane
    Soumerai, Jacob
    O'Connor, Kelly
    Munshi, Nikhil
    Richardson, Paul
    Anderson, Kenneth C.
    Witzig, Thomas E.
    Treon, Steven P.
    BLOOD, 2007, 110 (11) : 195B - 196B
  • [25] A phase II study of paclitaxel, oxaliplatin, leucovorin and 5-fluorouracil (POLF) in gemcitabine-refractory advanced pancreatic cancer
    Chue, Ben
    Grutsch, James
    Gupta, Digant
    Birdsall, John
    Lis, Christopher
    CANCER RESEARCH, 2009, 69
  • [26] SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)
    Ou, Sai-Hong Ignatius
    Moon, James
    Garland, Linda L.
    Mack, Philip C.
    Testa, Joseph R.
    Tsao, Anne S.
    Wozniak, Antoniette J.
    Gandara, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 387 - 391
  • [27] A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G)
    Iyer, R.
    Khushalani, N.
    Tan, W.
    Litwin, A.
    LeVea, C.
    Hutson, A.
    Tucker, C.
    Ma, W.
    Fakih, M.
    Adjei, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 391 - 391
  • [28] SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM).
    Garland, Linda L.
    Ou, Sai-Hong
    Moon, James
    Mack, Philip C.
    Testa, Joseph
    Tsao, Anne S.
    Wozniak, Antoinette J.
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells
    Chiong, Edmund
    Lee, I-Ling
    Dadbin, Ali
    Sabichi, Anita L.
    Harris, Loleta
    Urbauer, Diana
    McConkey, David J.
    Dickstein, Rian J.
    Cheng, Tiewei
    Grossman, H. Barton
    CLINICAL CANCER RESEARCH, 2011, 17 (09) : 2863 - 2873
  • [30] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
    Morizane, C.
    Okusaka, T.
    Furuse, J.
    Ishii, H.
    Ueno, H.
    Ikeda, M.
    Najima, M.
    Hirokawa, S.
    Nakachi, K.
    Ogura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 206S - 206S
12345